Development of Human T-Cell Leukemia Virus Type 1-Transformed Tumors in Rats following Suppression of T-Cell Immunity by CD80 and CD86 Blockade

Abstract

Host immunity influences clinical manifestations of human T-cell leukemia virus type 1 (HTLV-1

Graft-versus-Tax Response in Adult T-Cell Leukemia Patients after Hematopoietic Stem Cell Transplantation

“…In a recently established animal model for HTLV-I-infected T-cell tumors, we demonstrated an antitumor effect of Tax-specific CTL in vivo (24,25). In this model, otherwise fatal T-cell lymphomas in nude rats inoculated with syngeneic HTLV-I-infected cells could be eradicated by transferring fresh T cells from syngeneic immunocompetent rats vaccinated with either Tax-encoded DNA or peptides corresponding to a CTL epitope (26,27).…”

Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo

“…[85][86][87][88][89] In a more general manner, any factor that stimulates T cell proliferation in asymptomatic carriers may constitute a cofactor of ATLL. Recent works suggest that Strongyloides stercoralis might be one of these factors.…”

Potential immunogenicity of adult T cell leukemia cells in vivo

“…12,13 Vaccination with autologous HTLV-I-infected cells, 12 Tax-encoding DNA, 14 or oligopeptides corresponding to a CTL-epitope 15 elicited antitumor effects in this model. HTLV-I Tax serves as an immunodominant target antigen for HTLV-I-specific CTL not only in rats but also in humans.…”